Scorpio Tankers Inc. (NYSE:STNG) begin trading ex-dividend on May 22, 2014. A cash dividend payment of $0.09 per share is scheduled to be paid on June 12, 2014. Scorpio Tankers Inc. (NYSE:STNG) net profit margin is 8.20% and weekly performance is 1.59%. On last trading day company shares ended up $8.94. Analysts mean target price for the company is $-. Scorpio Tankers Inc. (NYSE:STNG) distance from 50-day simple moving average (SMA50) is -3.17%.
On May 9, 2014, Global Eagle Entertainment Inc. issued a press release (NASDAQ;ENT) announcing results for the quarter ended March 31, 2014. Global Eagle Acquisition Corp (NASDAQ:ENT) shares advanced 1.68% in last trading session and ended the day on $11.47. ENT gross Margin is 23.80% and its return on assets is -33.90%.Global Eagle Acquisition Corp (NASDAQ:ENT) quarterly performance is -34.12%.
Harbinger Group (NYSE:HRG) President Omar Asali sold 60,000 shares of the stock in a transaction that occurred on Thursday, May 22nd. The shares were sold at an average price of $11.58, for a total transaction of $694,800.00. Following the completion of the transaction, the president now directly owns 2,196,564 shares in the company, valued at approximately $25,436,211. Harbinger Group Inc. (NYSE:HRG) shares moved up 0.95% in last trading session and was closed at $11.71, while trading in range of $11.59 – $11.77. Harbinger Group Inc. (NYSE:HRG) year to date (YTD) performance is 1.39%.
Icahn Enterprises L.P. (NASDAQ:IEP) allows investors to take an ownership position in a part of Icahn’s operation. Icahn Enterprises LP (NASDAQ:IEP) ended the last trading day at $102.24. Company weekly volatility is calculated as 1.90% and price to cash ratio as 2.98.Icahn Enterprises LP (NASDAQ:IEP) showed a positive weekly performance of 3.18%.
Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, announced the successful completion of a Phase 1 study of LPCN 1107, the company’s oral hydroxyprogesterone caproate (HPC) product candidate. The study was designed to determine the pharmacokinetics and bioavailability of LPCN 1107 relative to an intramuscular (IM) HPC, as well as safety and tolerability, in healthy non-pregnant female volunteers. Lipocine Inc. (NASDAQ:LPCN) weekly performance is -7.04%. On last trading day company shares ended up $6.60. Analysts mean target price for the company is $25.00. Lipocine Inc. (NASDAQ:LPCN) distance from 50-day simple moving average (SMA50) is -13.09%.